Merck Serono Takes Action Against Illegal Online Drug Sales
This article was originally published in PharmAsia News
Executive Summary
Merck Serono China, subsidiary of Germany-based Merck, recently issued a statement revealing that some Chinese websites have been illegally selling drugs using the firm's brand names without its knowledge or permission. None of the drugs sold are developed, produced and marketed by Merck Serono, nor have they obtained the company's sales authorization. The websites and drugs include Moxue-Xianfuan by www.merckdx.com, Moxue-Mianfuan by www.merck-china.net and www.merckchina99.com, and Moxue-Meiluoxin by www.mxmnw.com. Merck Serono China has reported the illicit operations to relevant authorities and demanded severe punishments, with the rights to take further legal actions. (Click here for more - Chinese language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.